EconRx

Alzheimer's Boom or Bust


Listen Later

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

email: [email protected]

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

...more
View all episodesView all episodes
Download on the App Store

EconRxBy Aaron Young

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

12 ratings